Thin
1 / 1
Thymosin Alpha 1 is a 28-amino acid polypeptide initially isolated from thymic tissue. It is an important member of the thymosin family and primarily functions by regulating the immune system, enhancing T cell differentiation, maturation, and function, promoting cytokine production, and modulating innate and adaptive immune responses. It has a high safety profile and is commonly used clinically as an immune enhancer.
The drug's primary therapeutic areas focus on infectious diseases, cancer, and immunodeficiency-related diseases. Specifically, these include:
Used as adjunctive therapy for chronic hepatitis B (HBV) and chronic hepatitis C (HCV) to enhance vaccine response; also used for immune support in severe infections (such as sepsis) and respiratory infections.
As an adjunct to radiotherapy and chemotherapy, it is used to improve immunosuppressive states (such as advanced liver cancer, lung cancer, etc.) and enhance anti-tumor immunity.
Used as adjunctive therapy for primary immunodeficiency diseases and acquired immunodeficiency (such as immune reconstitution in HIV/AIDS patients).
In recent years, research has expanded to autoimmune diseases, immune regulation after severe viral infections such as COVID-19, and its application as a vaccine adjuvant.
The future development prospects of Thymosin Alpha 1 are promising, mainly focusing on the following areas:
Thymosin Alpha 1 is a 28-amino acid polypeptide initially isolated from thymic tissue. It is an important member of the thymosin family that functions primarily by regulating the immune system, enhancing T cell differentiation, and promoting cytokine production.
Yes, it has a high safety profile and is commonly used clinically as an immune enhancer to modulate innate and adaptive immune responses.
Its primary therapeutic areas focus on infectious diseases, oncology (cancer), and immunodeficiency-related diseases.
It acts as an adjunct to radiotherapy and chemotherapy to improve immunosuppressive states, such as in advanced liver and lung cancer, thereby enhancing anti-tumor immunity.
The development of long-acting sustained-release formulations and oral formulations (such as enteric-coated capsules) is expected to significantly improve patient compliance and expand its scope of application.
